EA
PRAX icon

Ellsworth Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Ellsworth Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,150
Closed -$627K – 204
2024
Q4 		$627K Buy
+8,150
New +$590K 0.16% 127

Other funds holding PRAX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ellsworth Advisors's PRAX Position: Q1 2025 in Review

Ellsworth Advisors sold out of Praxis Precision Medicines (PRAX) in Q1 2025, closing a stake of 8,150 shares — an estimated $627K sold.

Ellsworth Advisors first reported a position in PRAX in Q4 2024 and held it in 1 quarter. The position peaked at $627K in Q4 2024. 150 funds tracked by Wall St. Rank hold PRAX as of Q1 2025.

  • Ellsworth Advisors reported no remaining Praxis Precision Medicines position as of Q1 2025 after selling out during the quarter.
  • Ellsworth Advisors sold 8,150 Praxis Precision Medicines shares in Q1 2025, an estimated $627K.
  • Ellsworth Advisors first reported a position in Praxis Precision Medicines in Q4 2024 and held it in 1 quarter.
  • Ellsworth Advisors's Praxis Precision Medicines position peaked at $627K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2025.

Based on Ellsworth Advisors's 13F filing for Q1 2025, filed 28 May 2025.